Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Up 13.6% in January

Cellebrite DI Ltd. (NASDAQ:CLBT) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 1,170,000 shares, an increase of 13.6% from the December 31st total of 1,030,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is presently 0.9 days. Currently, 1.4% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Craig Hallum lifted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $21.57.

Cellebrite DI Stock Up 1.7 %

CLBT traded up $0.41 on Monday, reaching $24.45. The company had a trading volume of 807,412 shares, compared to its average volume of 1,501,623. Cellebrite DI has a 1 year low of $8.91 and a 1 year high of $24.62. The stock has a market capitalization of $5.04 billion, a PE ratio of -15.77, a P/E/G ratio of 3.55 and a beta of 1.47. The stock has a 50-day moving average price of $21.77 and a 200-day moving average price of $18.46.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $102.06 million. During the same period in the previous year, the company earned $0.09 earnings per share. Cellebrite DI’s quarterly revenue was up 27.0% compared to the same quarter last year. As a group, analysts expect that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock valued at $7,202,000 after buying an additional 75,092 shares during the last quarter. Telemark Asset Management LLC purchased a new stake in shares of Cellebrite DI in the third quarter valued at about $6,736,000. Two Sigma Advisers LP raised its holdings in shares of Cellebrite DI by 9.8% in the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after buying an additional 120,000 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after buying an additional 62,320 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Cellebrite DI by 7.3% in the third quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after buying an additional 30,052 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.